Research Article
Validation of Simultaneous Quantitative Method of HIV Protease Inhibitors Atazanavir, Darunavir and Ritonavir in Human Plasma by UPLC-MS/MS
Table 5
Relative matrix effect in different lots of human plasma at LLOQ level.
| Analyte
(nominal concentration) | Mean area response in six plasma lots (mean of three replicates) | Coefficient of
variation (%) | Accuracy (%) | | (1) K3EDTA | (2) K3EDTA | (3) K3EDTA | (4) K3EDTA | (5) Haemolysed | (6) Lipemic |
| | Atazanavir (5.0 ng/mL) | 3415 | 3368 | 3418 | 3497 | 3625 | 3707 | 3.82 | 100.86 | | Darunavir (5.0 ng/mL) | 6245 | 6351 | 6471 | 6152 | 6283 | 6373 | 1.76 | 98.82 | | Ritonavir (1.0 ng/mL) | 2004 | 2048 | 2105 | 2067 | 2117 | 2037 | 2.06 | 99.23 |
|
|
LLOQ: lower limit of quantitation.
|
